Navigation Links
Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
Date:8/12/2008

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision

Resources

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most significant driver of growth in the type 1 diabetes market will be the shift in the standard of care away from regular human insulins and neutral protamine Hagedorn (NPH) insulin to more-expensive rapid-acting insulin analogues and long-acting insulin analogues. Short-acting insulin analogues provide a more rapid onset of action than regular human insulin and long-acting insulin analogues require fewer injections than NPH insulin.

The new Pharmacor report entitled Type 1 Diabetes finds that market growth will be driven by rapid-acting insulin analogues that include Novo Nordisk's Novorapid/Novolog and Eli Lilly's Humalog as well as long-acting insulin analogues that include Sanofi-Aventis's Lantus and Novo Nordisk's Levemir. Since the type 1 diabetes market is saturated with effective and well-established insulin-based therapies that have been in use for decades, the report forecasts only modest 1.2 percent annual market growth through 2017.

According to the report, novel devices designed to allow needle-free administration of insulin could revolutionize treatment of type 1 diabetes, but their uptake will be hampered by physicians' negative experience with Pfizer/Nektar's inhaled insulin, Exubera, which fared poorly in the market owing to safety concerns and its premium price. Among the insulin-based therapies currently in the pipeline for type 1 diabetes, oral and transdermal insulins hold the greatest promise but their use will be constrained by dosing variability issues that are likely to dissuade physicians from prescribing them.

The report also finds that novel immunomodulators, particularly Diamyd Medical's DiamydT and DeveloGen/Andromeda Biotech's DiaPep-277, will drive growth in the Type 1 diabetes market. Through 2017, sales of DiamydT and DiaPep-277 will reach $45 million.

"Experts that we interviewed unanimously agree that the treatment of type 1 diabetes is characterized by a high level of unmet need for therapies that can halt the destruction of insulin-producing pancreatic-beta cells," said Caroline Gates, analyst at Decision Resources. "Immunomodulators have the potential to preserve beta-cell function, but their use will be hampered by long-term safety concerns, high prices and by the small number of eligible patients who would benefit from these agents."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
2. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Treatment Corrects Severe Insulin Imbalance in Animal Studies
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
7. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
8. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
9. Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions and the ... achieved through NPS and Dyax acquisitions and the announced combination ... through NPS and Dyax acquisitions and the announced combination with ... robust pipeline in Shire , s history   ... pipeline in Shire , s history   ...
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Florida Hospital ... Lightning take on the St. Louis Blues at the Amalie Arena. The puck drops ... inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA Heart ...
(Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
(Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):